ICUS supports the proposed OPTN policy change that will recognize contrast-enhanced ultrasound (CEUS) as an acceptable diagnostic imaging tool for evaluating hepatocellular carcinoma (HCC), and will align imaging classification criteria to the LI-RADS® terminology.
- We encourage you to submit a letter of support online prior to 11:59 PM ET on March 19, 2025, using the following link: https://optn.transplant.hrsa.gov/policies-bylaws/public-comment/updates-to-national-liver-review-board-guidance-and-further-alignment-with-li-rads/
OPTN is the Organ Procurement and Transplantation Network. The organization plays a crucial role in the evaluation and allocation of livers for transplantation. Additionally, OPTN guidelines and policies often have a broader impact on the clinical practice of hepatology and the use of CEUS to evaluate liver disease.
ICUS believes that the proposed OPTN policy change will eliminate a significant roadblock to the appropriate utilization of CEUS at a time when patient lives are at stake.
The OPTN policy update also will modernize liver imaging practices, align with best practices outlined in multiple international guidance statements, enhance patient safety and access to advanced, reliable imaging, and ultimately improve clinical outcomes.
CEUS is a safe, reliable, real-time, readily-available, radiation-free diagnostic imaging tool. Its sensitivity and specificity are comparable to contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) in diagnosis of HCC, and it provides decisive information in cases of indeterminate liver lesions. In addition, for patients with renal impairment or contraindications to iodinated or gadolinium-based contrast agents, CEUS may offer the only practical diagnostic imaging option.
Please join ICUS in supporting this important policy update.